Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAN 203

Next Previous
Search
Drug Profile

CAN 203

Alternative Names: CAN-203

Latest Information Update: 09 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CANbridge Pharmaceuticals; University of Massachusetts Medical School
  • Developer CANbridge Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Gene transference; SMN complex protein expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Spinal muscular atrophy

Most Recent Events

  • 03 May 2023 Pharmacodynamics data from preclinical studies in Spinal muscular atrophy released by CANbridge Pharmaceuticals
  • 03 Jan 2023 CANbridge Pharmaceuticals exercised its option to secure the exclusive global rights from UMass Chan Medical School for a novel second-generation gene therapy
  • 16 May 2022 Pharmacodynamics data from a preclinical study in Spinal muscular atrophy presented at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top